Concepts of Combating Chemoresistance in Cancer Therapeutics

Dr. Honey has pursued his Masters from Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala and earned his Ph.D. from University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh. He carries more than 15 years of teaching and research experience and serving as Head, Department of Pharmaceutics at University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot (a reputed Autonomous State Health University Organization of Punjab, India). His thrust areas of his research include targeted drug delivery, colon cancer biology and chemoprevention, using natural polymers, Dosage form designing based on oral disintegrating technology and colon drug delivery systems. He has published more than 55 international peer reviewed publications with 600+ citations, edited 01 book, published 15 book chapters and delivered talks/invited lectures at various national and international platforms. He has been also guiding many masters and PhD students Saurabh Srivastava is an Associate Professor of Pharmaceutics, at the National Institute of Pharmaceutical Education and Research, Hyderabad, India. His research interests include the development and optimization of industrially viable, feasible and scalable differentiated formulations, for the purpose of bioavailability enhancement, food effect minimization, repurposing/new indication, synergism for FDCs, and dose/dosing frequency reduction. Dr. Richu carries more than 15 years of teaching and research experience and serving as Scientist-C, at Multidisciplinary Research Unit, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India funded by Directorate of Health and Research, Govt. of India. She fetched major project as women-Scientist-A from Department of Science and Technology, Govt. Of India. She is involved in multi-disciplinary research and various projects from different departments with faculty of Guru Gobind Singh Medical College and Hospital. Her thrust areas of his research include Probiotics, Molecular biology, RNA interference, targeted drug delivery, colon cancer biology and chemoprevention, and colon drug delivery systems. She has published more than 20 international peer reviewed publications with 500+ citations, published 10 book chapters and delivered talks/invited lectures at various national and international platforms. She has fetched international travel grants from DST and DBT. She has been also guiding many masters and PhD students Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation” has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery.

• 1. Introduction to cancer drug resistance2. Mechanisms of multi drug resistance in cancer3. Therapeutic monitoring and adaptive strategies for combating drug resistance in cancer4. Novel therapeutic interventions to overcome drug resistance in cancer: Targeting key regulators of the apoptotic pathway5. Role of nutraceuticals in combating chemoresistance6. Microfluidic devices for cancer detection and monitoring via liquid biopsy assay7. Re-sensitization strategies towards autophagic resistance8. Re-sensitization of cancer cells in non-solid tumors9. Coupling of other modalities with chemotherapy to reverse chemoresistance10. Nanotechnology for overcoming acquired drug resistance in GIT cancers11. Nanotechnology for combating chemoresistance in peripheral cancers12. Nanotechnology for combating chemoresistance in ovarian cancer13. Nanotechnology for overcoming acquired drug resistance in CNS cancers14. Advanced Strategies to improve the accumulation of nanotherapeutics in tumor15. In silico-assisted prediction of chemoresistance